Gene · 80339
Papers3,957
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 3,957
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Oxidative gaseous air pollutant exposure interacts with PNPLA3-I148M genotype to influence liver fat fraction and multi-omics profiles in young adults. | Environ Pollut | 2025 | 39864653 | PubTator, text mining | PubMed |
| Metabolic dysfunction-associated steatotic liver disease in children. | Gut | 2025 | 39848671 | PubTator, text mining | PubMed |
| Genetic risk amplifies lifestyle effects on hepatic steatosis and its progression: Insights from a population-based cohort. | Dig Liver Dis | 2025 | 39837741 | PubTator, text mining | PubMed |
| Unlocking the influence of PNPLA3 mutations on lipolysis: Insights into lipid droplet formation and metabolic dynamics in metabolic dysfunction-associated steatotic liver disease. | Biochim Biophys Acta Gen Subj | 2025 | 39832620 | PubTator, text mining | PubMed |
| Lipid droplet targeting of the lipase coactivator ABHD5 and the fatty liver disease-causing variant PNPLA3 I148M is required to promote liver steatosis. | J Biol Chem | 2025 | 39814233 | PubTator, text mining | PubMed |
| Impact of NAFLD-related SNPs on the carotid atherosclerosis development; a five-year prospective observational study. | Atheroscler Plus | 2025 | 39802653 | PubTator, text mining | PubMed |
| AZD2693, a PNPLA3 antisense oligonucleotide, for the treatment of MASH in 148M homozygous participants: Two randomized phase I trials. | J Hepatol | 2025 | 39798707 | PubTator, text mining | PubMed |
| Genetic Risk Factors for Metabolic Dysfunction-Associated Steatotic Liver Disease. | Gut Liver | 2025 | 39774124 | PubTator, text mining | PubMed |
| Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study. | Hepatol Int | 2025 | 39755997 | PubTator, text mining | PubMed |
| Dissecting the shared genetic architecture between nonalcoholic fatty liver disease and type 2 diabetes. | Hum Mol Genet | 2025 | 39690818 | PubTator, text mining | PubMed |
| Deep metabolic phenotyping of humans with protein-altering variants in TM6SF2 using a genome-first approach. | JHEP Rep | 2025 | 39687601 | PubTator, text mining | PubMed |
| PNPLA3 in Alcohol-Related Liver Disease. | Liver Int | 2025 | 39679853 | PubTator, text mining | PubMed |
| Type 2 diabetes and the minor allele of PNPLA3 consistently identify high-risk metabolic dysfunction associated steatotic liver disease. | Diabetes Res Clin Pract | 2025 | 39675485 | PubTator, text mining | PubMed |
| Preclinical and Clinical Pharmacokinetics of JNJ-75220795, an siRNA Therapeutic Targeting PNPLA3, for Metabolic Dysfunction-Associated Steatohepatitis. | J Clin Pharmacol | 2025 | 39654352 | PubTator, text mining | PubMed |
| PNPLA3 and SAMM50 variants are associated with lean nonalcoholic fatty liver disease in Asian population. | Ann Hepatol | 2025 | 39638042 | PubTator, text mining | PubMed |
| Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis. | Liver Int | 2025 | 39605307 | PubTator, text mining | PubMed |
| Statin-associated regulation of hepatic PNPLA3 in patients without known liver disease. | J Intern Med | 2025 | 39560367 | PubTator, text mining | PubMed |
| PNPLA3 I148M Interacts With Environmental Triggers to Cause Human Disease. | Liver Int | 2025 | 39559944 | PubTator, text mining | PubMed |
| PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis. | J Hepatol | 2025 | 39550037 | PubTator, text mining | PubMed |
| Impact of PNPLA3 in Lean Individuals and in Cryptogenic Steatotic Liver Disease. | Liver Int | 2025 | 39540675 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/80339/papers?page=16